Skip to content

Add your earlier progress to your account?

From before you signed in, this browser has:

Which plan do you want to keep?

You answered the plan questions before signing in. These answers differ from the plan saved on your account.

SettingSaved planNew answers

Study progress is waiting to be saved

Enzyme Kinetics and Diagnostic Enzymology

About 17 min · 18 sections · 3 self-checks

On this page

An enzyme result on the report is a reaction rate, measured under one method's defined conditions. Substrate concentration, pH, temperature, cofactors, reaction direction, and the detection system affect the reported activity. To interpret an enzyme result, consider how it was measured, where the enzyme occurs in the body, whether the specimen is suitable, and how the result fits with related tests.

Enzyme structure and classification

An enzyme binds its substrate at an active site and lowers the activation energy needed to reach the reaction's transition state. Binding commonly changes the shape of the active site through induced fit. Some enzymes also have an allosteric site where another molecule changes catalytic activity. The amino acids that form one active site can come from different regions of one polypeptide or from different subunits of a multimeric enzyme. Enzyme specificity ranges from a single substrate to a group of related substrates or one type of chemical bond.

Many enzymes require a nonprotein component:

  • An activator is an inorganic ion needed for activity, such as magnesium or zinc.
  • A coenzyme is an organic participant, often derived from a vitamin. A tightly bound coenzyme is a prosthetic group.
  • An apoenzyme is the protein portion alone. The active enzyme with its required component is the holoenzyme.
  • A zymogen is an inactive precursor that becomes active after a biochemical change, commonly proteolytic cleavage. This delays activity until the enzyme reaches the proper tissue or pathway.

The International Union of Biochemistry and Molecular Biology assigns a four-part Enzyme Commission (EC) number that identifies class, subclass, sub-subclass, and the enzyme's serial entry. The current system has seven major classes.1

EC class Reaction type Clinical laboratory example
1. Oxidoreductases Transfer electrons or hydrogen Lactate dehydrogenase, glucose-6-phosphate dehydrogenase
2. Transferases Transfer a chemical group Aspartate aminotransferase, alanine aminotransferase, creatine kinase, gamma-glutamyl transferase
3. Hydrolases Cleave a bond with water Alkaline phosphatase, amylase, lipase, cholinesterase
4. Lyases Add or remove groups while forming or breaking a double bond Aldolase
5. Isomerases Rearrange a molecule into an isomer Triosephosphate isomerase
6. Ligases Join two molecules, usually with energy from a nucleoside triphosphate Glutathione synthetase
7. Translocases Move ions or molecules across membranes or separate them within membranes Sodium-transporting ATPase

Multiple enzyme forms. Isoenzymes, also called isozymes, are genetically determined forms that catalyze the same reaction and differ in primary structure. Electrophoretic mobility, heat stability, inhibitor response, and antibody recognition can separate them. Post-translationally modified forms, zymogens, polymers, and enzyme-protein complexes are other molecular forms and require more specific names.2

Reaction rates

For a simple one-substrate reaction, enzyme and substrate form a reversible complex before product is released:

E + S ES → E + P

At low substrate concentration, reaction velocity rises nearly in proportion to substrate concentration. As active sites become occupied, the rate approaches a maximum velocity, Vmax. Michaelis-Menten kinetics describe this relationship:

v = (Vmax × [S]) ÷ (Km + [S])

In this ideal model, Km is the substrate concentration at one-half Vmax. A lower Km often indicates greater apparent substrate affinity under the same model and assay conditions. Km and a binding dissociation constant coincide only under restricted kinetic conditions.3

v = (160 U/L × 15.0 mmol/L) ÷ (5.0 mmol/L + 15.0 mmol/L) = 120 U/L

The measured rate is 75% of Vmax.

The historical Lineweaver-Burk plot graphs 1/v against 1/[S]:

1/v = (Km/Vmax)(1/[S]) + 1/Vmax

The y-intercept is 1/Vmax, the x-intercept is −1/Km, and the slope is Km/Vmax. Reciprocal transformation gives disproportionate weight to observations at low substrate concentration, so direct nonlinear fitting of the Michaelis-Menten curve is generally preferred.

Idealized inhibition patterns

The classic inhibition patterns describe simplified steady-state models. Real enzymes can show additional binding and regulatory behavior.3

Inhibition pattern Binding in the ideal model Vmax Apparent Km Effect of added substrate
Competitive Free enzyme at the active site Unchanged Increased Can restore the rate toward Vmax
Pure noncompetitive Free enzyme and ES with equal affinity Decreased Unchanged Cannot restore Vmax
Mixed Free enzyme and ES with unequal affinity Decreased Increased or decreased Cannot restore Vmax
Uncompetitive ES complex Decreased Decreased Cannot restore Vmax
Enzyme saturation and inhibitionEnzyme saturation and inhibitionReaction velocity at different substrate concentrations.v = Vmax × [S] ÷ (Km + [S])Substrate concentration [S] (mmol/L)Reaction velocity v (U/L)010203040080160At Km, v = Vmax / 2No inhibitorVmax 160 U/LKm 5 mmol/LCompetitiveVmax unchangedApparent Km 15 mmol/LPure noncompetitiveVmax 80 U/LKm unchanged at 5 mmol/LThe competitive curve approaches the same asymptote at higher [S].These are idealized Michaelis-Menten models.5
Substrate saturation for the example enzyme with Vmax 160 U/L and Km 5.0 mmol/L, beside the same enzyme with illustrative inhibitors: a competitive inhibitor that raises the apparent Km to 15 mmol/L without changing Vmax, and a pure noncompetitive inhibitor that halves Vmax to 80 U/L without changing Km.

Temperature, pH, ionic strength, reaction time, substrate concentration, and cofactor concentration also change activity. The validated procedure defines each condition. Many higher-order reference procedures for common clinical enzymes operate at 37 °C. Routine results remain traceable only to their stated measurement procedure.4

Measuring catalytic activity

Enzyme activity assays usually measure the initial linear reaction rate while substrate and required cofactors are present in sufficient excess. Excessive substrate depletion, product accumulation, inhibitor carryover, or departure from the method's linear range can lower the apparent activity. The analyzer follows the reaction directly or links it to an indicator reaction whose product can be measured.

When substrate concentration is well below Km, the reaction is approximately first order with respect to substrate. When substrate is saturating, the reaction is approximately zero order with respect to substrate, and the rate depends chiefly on enzyme amount. Activity assays use this saturating region so the specimen enzyme controls the measured rate.

NADH and NADPH absorb strongly near 340 nm. Their oxidized forms have little absorbance there. Many coupled methods therefore follow a rise or fall in absorbance at 340 nm. Other assays use a colored substrate or couple the reaction to a dye measured at another wavelength.

Measurement design How the signal is obtained Main control
Direct kinetic method The primary reaction changes absorbance or another signal Verify a linear change over the read interval
Coupled kinetic method One or more indicator reactions convert the primary product into a measurable species Supply coupling enzymes and cofactors in enough excess to keep the measured enzyme rate-limiting
Fixed-time method The reaction proceeds for a defined interval before a single measurement Control timing and confirm that the interval stays within the validated response range

The unit (U) is the catalytic activity that converts 1 µmol of substrate per minute under the specified conditions. The coherent SI unit is the katal (kat), equal to 1 mol/s. The Bureau International des Poids et Mesures specifies that a katal result must identify the measurement procedure and indicator reaction.5

1 U = 1 µmol/min = 16.67 nmol/s = 16.67 nkat

A creatine kinase activity of 240 U/L equals:

240 ÷ 60 = 4.0 µmol·s−1·L−1 = 4.0 µkat/L = 4,000 nkat/L

Activity results depend on reaction conditions even when laboratories report the same unit. International Federation of Clinical Chemistry and Laboratory Medicine higher-order procedures and reference materials support traceability for several enzyme measurands. Routine procedures can still differ in substrate, cofactor activation, calibration, and response to molecular forms.4

The absorbance calculation behind these measurements appears in Core Chemistry Calculations. Enzymes are also used as reagents in assays for glucose, cholesterol, triglycerides, and uric acid, and as labels that amplify signals in immunoassays.

Reference intervals and specimen rules

Apply the reference interval your laboratory verified for its patient population, specimen, and method. Under the Clinical Laboratory Improvement Amendments, a laboratory verifies applicable manufacturer performance specifications before reporting patient results from an unmodified cleared or approved test system. It establishes the applicable specifications when it modifies a test, uses an unapproved method, develops a method in house, or lacks suitable manufacturer specifications. Reference intervals are among the specifications addressed when applicable.6

The same method-specific rule applies to specimen type, storage, hemolysis, lipemia, icterus, linearity, dilution, and reporting limits. A universal enzyme interval or specimen correction would hide clinically important differences among procedures.

Creatine kinase and lactate dehydrogenase

Creatine kinase

Creatine kinase (CK) transfers phosphate between creatine and adenosine triphosphate:

Creatine + ATP phosphocreatine + ADP

CK activity is greatest in skeletal muscle, cardiac muscle, and brain. Total serum CK is used to evaluate and monitor muscle injury. Exercise, intramuscular injections, surgery, seizures, trauma, medications, muscle mass, age, and sex can change the result. A current coupled procedure runs the reaction toward ATP formation, then uses hexokinase and glucose-6-phosphate dehydrogenase to form NADPH for photometric measurement.7

CK form Subunits Main tissue association Laboratory meaning
CK-MM M + M Skeletal muscle; also cardiac muscle Dominant circulating form; increases with skeletal-muscle injury
CK-MB M + B Cardiac muscle; smaller contribution from skeletal muscle Historical cardiac marker; skeletal-muscle injury and macroforms can also increase or distort the result
CK-BB B + B Brain and several visceral tissues Usually low in serum; specialized interpretation is required when detected
Mitochondrial CK Mitochondrial form Energy transfer within mitochondria Can produce an atypical electrophoretic band during major tissue injury

Common laboratory definitions of rhabdomyolysis include CK greater than 5 times the upper reference limit or greater than 1,000 U/L. Serial measurements establish the peak and subsequent decline, with interpretation tied to muscle injury, kidney function, urine findings, and the local clinical protocol.8

CK-MB activity fractions and isoform ratios are historical myocardial infarction markers. Current acute coronary syndrome guidance identifies cardiac troponin, preferably a high-sensitivity assay, as the biomarker of choice. A troponin value above the assay's 99th-percentile upper reference limit indicates myocardial injury, and serial change supports classification of an acute process.9

Significant hemolysis can interfere with CK measurement. The analyzer's hemolysis limit and reagent design determine whether the specimen can be reported.7

Lactate dehydrogenase

Lactate dehydrogenase is commonly abbreviated LD in laboratory reporting and LDH in clinical prose. It catalyzes the reversible reaction:

Lactate + NAD+ pyruvate + NADH + H+

A procedure can follow NADH formation in the lactate-to-pyruvate direction or NADH consumption in the reverse direction. Reaction direction and substrate concentration are part of the method. LD occurs throughout the body, including erythrocytes, liver, heart, skeletal muscle, kidney, and lung, so total activity has broad sensitivity and limited tissue specificity.10

Five cytosolic isoenzymes are tetramers of heart-type H and muscle-type M subunits:

Isoenzyme Subunits Main associations
LD-1 H4 Heart, erythrocytes, kidney
LD-2 H3M Heart, erythrocytes, kidney
LD-3 H2M2 Lung and several other tissues
LD-4 HM3 Leukocytes, lymph nodes, muscle, liver
LD-5 M4 Liver and skeletal muscle

Electrophoresis separates these fractions. Tissue associations overlap, so an isoenzyme pattern narrows possible sources without identifying one organ by itself.11

An LD-1 activity greater than LD-2 was historically called a flipped pattern and was used in late myocardial infarction evaluation. Hemolysis and megaloblastic processes can produce the same pattern. Cardiac troponin has replaced it as the marker of cardiac injury.9,11

Erythrocytes contain abundant LD. Even modest in vitro hemolysis can increase serum or plasma activity and alter an isoenzyme pattern. Separation time, storage temperature, and rejection limits follow the performing method. Check the hemolysis index before you release an LD result.10,11

Hepatobiliary and bone enzyme patterns

Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), and 5′-nucleotidase are markers of tissue injury, enzyme induction, or cholestasis. Hepatic function is measured separately, by tests such as albumin and clotting-factor activity. Aminotransferase magnitude alone is an unreliable measure of the extent of liver injury.12

Aminotransferases

AST and ALT transfer amino groups with pyridoxal-5′-phosphate as a coenzyme:

Aspartate + 2-oxoglutarate oxaloacetate + glutamate

Alanine + 2-oxoglutarate pyruvate + glutamate

Kinetic AST methods commonly couple oxaloacetate reduction to malate dehydrogenase. ALT methods couple pyruvate reduction to LD. Both follow NADH consumption near 340 nm. Reagents can include pyridoxal-5′-phosphate activation, which changes measured activity and affects comparison among methods.13,14

ALT has its greatest tissue concentration in the liver and is more liver specific than AST. AST also occurs in skeletal muscle, cardiac muscle, erythrocytes, kidney, and other tissues. Hemolysis and muscle injury can therefore increase AST with a smaller ALT response. A hepatocellular pattern has AST and ALT increased out of proportion to ALP. A cholestatic pattern has ALP increased out of proportion to the aminotransferases. The AST:ALT ratio can contribute to interpretation. Assigning a cause requires the remaining laboratory and clinical findings.15

Alkaline phosphatase, GGT, and 5′-nucleotidase

ALP hydrolyzes phosphate monoesters under alkaline assay conditions. Colorimetric methods commonly use p-nitrophenyl phosphate, with pH, cofactors, wavelength, and calibration specified by the reagent system. Liver and bone supply most clinically important serum ALP activity. Intestinal and placental forms can also contribute.

Age and sex are needed for interval selection because osteoblastic activity during skeletal growth raises ALP in childhood and adolescence. Pregnancy can add placental ALP. When total ALP is increased, electrophoresis can separate liver, bone, and intestinal fractions, and specialized methods can measure bone-specific ALP.16

GGT transfers a gamma-glutamyl group to an acceptor. Routine kinetic methods use a prepared gamma-glutamyl donor and a chromogenic product. Serum GGT primarily reflects the hepatobiliary system, although kidney tissue has high enzyme activity. An increased GGT accompanying increased ALP supports a hepatobiliary source. A normal GGT suggests bone or another source. Enzyme-inducing drugs and alcohol exposure can increase GGT, which limits its specificity. Current liver guidance uses GGT as a clarifying test for ALP source and avoids isolated GGT as a general screening result.15,17

Serum 5′-nucleotidase hydrolyzes 5′-nucleotides. Increased activity can support a hepatobiliary source for an ALP increase because bone disease generally leaves 5′-nucleotidase within its method-specific interval. Availability, specimen type, anticoagulant acceptance, and interference limits vary by procedure.18

The connected bilirubin and urobilinogen patterns appear in Heme Synthesis, Porphyrias, and Bilirubin.

Acid phosphatase

Prostatic acid phosphatase was used historically in prostate cancer evaluation before prostate-specific antigen became the principal blood marker. Current prostatic acid phosphatase use is specialized and indication-specific.19,20

Pancreatic enzymes

Amylase and lipase are used to evaluate pancreatic injury. Diagnosis of acute pancreatitis requires at least two of three findings: characteristic pain, serum amylase or lipase at least 3 times the assay's upper reference limit, and characteristic imaging. Lipase is generally preferred because it has greater pancreatic specificity and remains increased longer.21

Amylase

Alpha-amylase hydrolyzes internal alpha-1,4 glycosidic bonds in starch and related polysaccharides. Pancreas and salivary glands supply the main circulating forms. Current activity methods use defined chromogenic oligosaccharides, sometimes with coupling enzymes, and measure product formation as a rate. Substrate, calcium dependence, accepted anticoagulants, and wavelength vary by method. Historical amyloclastic methods followed loss of the starch-iodine color, and saccharogenic methods measured reducing sugars.22

Amylase can rise within hours of acute pancreatic injury and often returns toward baseline within 3 to 5 days. Renal impairment, salivary disease, abdominal disease, and macroamylasemia can also increase serum activity. Hypertriglyceridemia can suppress some amylase methods. Pancreatic and salivary isoamylase measurement can help identify the source of a persistent or discordant result. 22

Macroamylase is a high-molecular-mass complex with reduced renal clearance. A pattern of persistently increased serum amylase with relatively low urine amylase can support its presence. Paired clearance calculations and cutoffs remain method specific.22

Lipase

Pancreatic lipase hydrolyzes triglycerides. Activity depends on an appropriate emulsified substrate, and many methods add colipase and a bile salt or detergent to improve the pancreatic response. Assays use colorimetric or turbidimetric designs. The specific substrate and indicator reaction determine the wavelength and interference profile.23

Lipase commonly rises within hours of acute pancreatitis and remains increased longer than amylase. Kidney disease and reduced clearance can raise lipase without acute pancreatic injury. Gross hemolysis and other specimen effects follow the assay's stated limits. Serial enzyme magnitude alone is an unreliable measure of pancreatitis severity.23

Other measured enzyme activities

Activity Laboratory use Main interpretation limits
Angiotensin-converting enzyme (ACE) Adjunctive measurement during selected sarcoidosis evaluations Other diseases can increase ACE; ACE-inhibitor drugs can produce very low activity; the result is insufficient to establish sarcoidosis
Erythrocyte glucose-6-phosphate dehydrogenase (G6PD) Quantitative red-cell enzyme measurement for G6PD deficiency Reticulocytosis, transfusion, leukocyte contamination, method, and X-chromosome mosaicism affect interpretation

ACE is a zinc-dependent peptidase that forms angiotensin II from angiotensin I and inactivates bradykinin. Activity methods use laboratory-made peptide substrates. Increased serum activity can occur in sarcoidosis and several other disorders. ACE-inhibitor treatment can markedly suppress the result. The assay remains an adjunct interpreted with the diagnostic evaluation.24

Diagnostic G6PD measurement uses erythrocytes in whole blood and commonly follows NADPH production near 340 nm. Serum and erythrocyte G6PD are different measurands, so an erythrocyte reference interval does not apply to serum. The full phenotypic and hematologic interpretation appears in Hemolytic and Hypoproliferative Anemias, Erythrocytosis, and Hemoglobin Variants.25

Macroenzymes

A persistent, stable increase in a single enzyme without corresponding tissue injury suggests a macroenzyme: a high-molecular-mass form whose size slows clearance and can produce persistent serum activity. Type 1 macroenzymes are commonly enzyme-immunoglobulin complexes. Type 2 forms include enzyme complexes with lipoproteins or other nonimmunoglobulin partners and self-polymerized enzyme. Macroforms have been reported for amylase, AST, ALT, ALP, GGT, CK, LD, lipase, and other activities.26

The macroform can respond differently from the free enzyme in an activity assay, so the size of the increase depends on the method.

Polyethylene glycol (PEG) precipitation is a common first screen. PEG removes immunoglobulins and some associated enzyme activity, so compare activity before and after precipitation. The result requires an enzyme-specific limit validated for the local PEG protocol, analyzer, age group, and population. A universal percentage cutoff is unsuitable. Electrophoresis, gel filtration, ultrafiltration, or immunochemical studies can characterize an unresolved form.26 Before you report an isolated, persistent enzyme increase as tissue injury, consider a macroenzyme as the cause.

Practice

Check yourself 1 of 3

In a Michaelis-Menten model, Vmax is 120 U/L and Km is 4 mmol/L. What is the reaction velocity (v) at a substrate concentration of 8 mmol/L?

Correct. v = (120 × 8) ÷ (4 + 8) = 960 ÷ 12 = 80 U/L, two-thirds of Vmax.

Incorrect. (120 × 8) ÷ 4 = 240 U/L leaves substrate out of the denominator and gives a rate above Vmax, which the model never reaches.

Incorrect. That is half of Vmax, the velocity when substrate equals Km. Here substrate is twice Km.

Review this section

Check yourself 2 of 3

Which change describes ideal competitive inhibition?

Incorrect. That is the ideal pure noncompetitive pattern, in which the inhibitor binds free enzyme and the enzyme-substrate complex with equal affinity.

Correct. The inhibitor binds free enzyme at the active site, so added substrate can restore the rate toward the unchanged Vmax.

Incorrect. That is the ideal uncompetitive pattern, in which the inhibitor binds the enzyme-substrate complex.

Review this section

Check yourself 3 of 3

Alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) are both increased. What does the GGT result contribute?

Correct. An increased GGT beside an increased ALP supports a hepatobiliary source. Alcohol and enzyme-inducing drugs also raise GGT, which limits its specificity.

Incorrect. Bone disease leaves GGT within its interval, so a raised ALP with a GGT inside its interval suggests a bone source.

Incorrect. A hepatocellular pattern is read from the aminotransferases (AST and ALT) increased out of proportion to ALP. GGT helps identify the source of the ALP.

Review this section

References
  1. Nomenclature Committee of the International Union of Biochemistry and Molecular Biology. Enzyme Nomenclature. Accessed August 29, 2026. Back to text
  2. Nomenclature Committee of the International Union of Biochemistry and Molecular Biology. Multiple Forms of Enzymes. Accessed August 29, 2026. Back to text
  3. International Union of Biochemistry and Molecular Biology. Recommendations on Biochemical and Organic Nomenclature, Symbols and Terminology: Enzyme Kinetics. Accessed August 29, 2026. Back to text
  4. Joint Committee for Traceability in Laboratory Medicine. Enzyme reference measurement procedures and materials. Accessed August 29, 2026. Back to text
  5. Bureau International des Poids et Mesures. Resolution 12 of the 21st CGPM: Special name for the SI derived unit mole per second, the katal, for the expression of catalytic activity. 1999. doi:10.59161/CGPM1999RES12E Back to text
  6. Centers for Medicare & Medicaid Services. State Operations Manual, Appendix C: Survey Procedures and Interpretive Guidelines for Laboratories and Laboratory Services. Rev 236. Issued January 23, 2026. Accessed August 29, 2026. Back to text
  7. Mayo Clinic Laboratories. Creatine Kinase (CK), Serum. Accessed August 29, 2026. Back to text
  8. Kodadek L, Carmichael SP II, Seshadri A, et al. Rhabdomyolysis: an American Association for the Surgery of Trauma Critical Care Committee clinical consensus document. Trauma Surg Acute Care Open. 2022;7(1):e000836. doi:10.1136/tsaco-2021-000836 Back to text
  9. Rao SV, O'Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndromes. J Am Coll Cardiol. 2025;85(22):2135-2237. doi:10.1016/j.jacc.2024.11.009 Back to text
  10. Mayo Clinic Laboratories. Lactate Dehydrogenase (LDH), Serum. Accessed August 29, 2026. Back to text
  11. Labcorp. Lactate Dehydrogenase (LD) Isoenzymes. Accessed August 29, 2026. Back to text
  12. Rosario D. How to approach elevated liver enzymes? American Association for the Study of Liver Diseases. January 17, 2025. Accessed August 29, 2026. Back to text
  13. Mayo Clinic Laboratories. Aspartate Aminotransferase (AST) (GOT), Serum. Accessed August 29, 2026. Back to text
  14. Mayo Clinic Laboratories. Alanine Aminotransferase (ALT) (GPT), Serum. Accessed August 29, 2026. Back to text
  15. Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol. 2017;112(1):18-35. doi:10.1038/ajg.2016.517 Back to text
  16. Mayo Clinic Laboratories. Alkaline Phosphatase, Total and Isoenzymes, Serum. Accessed August 29, 2026. Back to text
  17. Mayo Clinic Laboratories. Gamma-Glutamyltransferase, Serum. Accessed August 29, 2026. Back to text
  18. Mayo Clinic Laboratories. 5′-Nucleotidase, Serum. Accessed August 29, 2026. Back to text
  19. National Cancer Institute. Prostate-Specific Antigen Test. Updated January 31, 2025. Accessed August 29, 2026. Back to text
  20. Mayo Clinic Laboratories. Prostatic Acid Phosphatase, Serum. Accessed August 29, 2026. Back to text
  21. Tenner S, Vege SS, Sheth SG, et al. American College of Gastroenterology guidelines: management of acute pancreatitis. Am J Gastroenterol. 2024;119(3):419-437. doi:10.14309/ajg.0000000000002645 Back to text
  22. Mayo Clinic Laboratories. Amylase, Total, Serum. Accessed August 29, 2026. Back to text
  23. Mayo Clinic Laboratories. Lipase, Serum. Accessed August 29, 2026. Back to text
  24. Mayo Clinic Laboratories. Angiotensin Converting Enzyme, Serum. Accessed August 29, 2026. Back to text
  25. Mayo Clinic Laboratories. Glucose 6-Phosphate Dehydrogenase Enzyme Activity, Blood. Accessed August 29, 2026. Back to text
  26. Dedeene L, Stockman M, Steels S, Vermeersch P, Frans G. Detection of macroenzymes: establishing upper reference limits for eight enzymes after polyethylene glycol precipitation. Biochem Med (Zagreb). 2023;33(1):010705. doi:10.11613/BM.2023.010705 Back to text

End of Enzyme Kinetics and Diagnostic Enzymology

Back to top ↑

Saved lessonsReview and reuse

Enlarged figure